Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
04:01pm, Tuesday, 26'th May 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued
09:21pm, Friday, 22'nd May 2026
On May 22, 2026, Delcath Systems Inc (DCTH) shares fell 3.8%, bringing the current price to $11.02. The stock's performance over the last year has been disappoi
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 15'th May 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
08:00am, Tuesday, 12'th May 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
11:31pm, Thursday, 07'th May 2026
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
12:16pm, Thursday, 07'th May 2026
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
08:00am, Thursday, 07'th May 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha
Delcath Systems to Host First Quarter 2026 Earnings Call
08:30am, Thursday, 23'rd Apr 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT®
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
08:30am, Wednesday, 01'st Apr 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Soc
Contrasting Delcath Systems (NASDAQ:DCTH) & ADB International Group (OTCMKTS:EQUR)
01:30am, Monday, 23'rd Mar 2026
Delcath Systems (NASDAQ: DCTH - Get Free Report) and ADB International Group (OTCMKTS:EQUR - Get Free Report) are both medical companies, but which is the better investment? We will compare the two co
Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.50 Average PT from Analysts
02:50am, Thursday, 05'th Mar 2026
Delcath Systems, Inc. (NASDAQ: DCTH - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat Ratings reports. One investme
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
08:00am, Tuesday, 03'rd Mar 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic live
Delcath: Fundamentals Intact, Despite Share Price Weakness
03:42pm, Monday, 02'nd Mar 2026
Delcath Systems, Inc.'s revenue remains under pressure due to weak patient starts in the third quarter of 2025. The fundamentals of the company remain intact, though, and 2026 should be another year o
